Gene variant protects against type 2 diabetes, heart disease, and hypertriglyceridemia

April 25, 2006

Boston, MA -- A rare gene variant in humans helps to protect against two of the country's top killers -- type 2 diabetes and heart disease -- as well as against hypertriglyceridemia, a condition that increases the risk of heart disease, obesity, and pancreatitis. A team of researchers from Harvard School of Public Health (HSPH) and the Channing Laboratory published their findings in this week's issue of the Proceedings of the National Academy of Sciences.

Individuals who had the gene variant had 12 percent lower levels of triglycerides in their blood serum than subjects who did not have the variant. Risk of heart disease was 34 percent lower for those with the variant. Risk for type 2 diabetes was 48 percent lower among obese individuals when compared to other obese individuals who did not have the variant.

"This is a perfect example of the interdisciplinary studies between population sciences, nutrition, and basic scientists at HSPH," said Gökhan Hotamisligil, a senior author and James Stevens Simmons Professor of Genetics and Metabolism. The lead author was HSPH Research Associate Gurol Tuncman.

The gene was first identified in mouse studies as a mediator of metabolic disease. Mice that lack this gene, which encodes for a lipid-binding protein called aP2, were partially resistant to type 2 diabetes and exhibited strong protection against atherosclerosis. The HSPH and Channing team -- representing scientific contributions from five separate research groups -- investigated whether the same held true in humans. They reviewed the medical and genetic records and studied the genetic material of 7,899 participants in the Nurses' Health Study and the Health Professionals Follow-Up Study. Of the group, 4.3 percent had the variant.

The team utilized molecular and cellular techniques in fat cells as well as in human fat tissue samples. They found that the variant T-87C, which sits on the promoter region of the gene that produces the aP2 protein, interferes with the gene and results in less production of aP2 in individuals that carry this variant.

"In other words, this genetic variant in humans looked like a milder version of the mouse knockout model," said Eric Rimm, HSPH Associate Professor of Epidemiology and Nutrition.

In the U.S., more than 65 percent of adults and 16 percent of children are overweight. Nearly 24 percent of adults have metabolic syndrome, a constellation of conditions that includes obesity, insulin resistance, and hypertension.

The identification of the T-87C variant indicates that aP2 might play a similar role in humans as it does in mice. The significance of this finding may include a potential target for drugs designed to reduce aP2 levels, offering a possible means to protect against some of the world's most prevalent chronic diseases, say the authors.
-end-
This work was supported in part by grants from the Iacocca Foundation, NIH, and American Diabetes Association. Samples used from the Nurses' Health Study and Health Professionals Follow-Up Study were supported by NIH grants. Lead author Gurol Tuncman is a recipient of a postdoctoral fellowship from the Iacocca Foundation to conduct this interdisciplinary project and was supervised by both Rimm and Hotamisligil.

Harvard School of Public Health is dedicated to advancing the public's health through learning, discovery, and communication. More than 300 faculty members are engaged in teaching and training the 900-plus student body in a broad spectrum of disciplines crucial to the health and well being of individuals and populations around the world. Programs and projects range from the molecular biology of AIDS vaccines to the epidemiology of cancer; from risk analysis to violence prevention; from maternal and children's health to quality of care measurement; from health care management to international health and human rights.

Harvard T.H. Chan School of Public Health

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.